Research ArticleResearch Article

Gemcitabine and Docetaxel as a Second-Line Treatment in Advanced Soft Tissue Sarcomas

Hend Ahmed El-Hadaad and Hanan AHMED WAHBA
Clinical Oncology and Cancer Research September 2011, 8 (3) 133-137; DOI: https://doi.org/10.1007/s11805-011-0571-y

References

  1. ↵
    1. Singer S,
    2. Demetri GD,
    3. Baldini EH, et al.
    Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 2000; 1: 75–85.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Clark MA,
    2. Fisher C,
    3. Judson I, et al.
    Soft tissue sarcomas in adults. N Engl J Med 2005; 353: 707–711.
    OpenUrl
  3. ↵
    1. Blay JY,
    2. van Glabbeke M,
    3. Verweij J, et al.
    Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64–69.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Schiff PB,
    2. Fant J,
    3. Horwitz SB.
    Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665–667.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Rowinsky EK,
    2. Onetto N,
    3. Canetta RM, et al.
    Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646–662.
    OpenUrlPubMedWeb of Science
  6. ↵
    1. Heinemann V,
    2. Hertel LW,
    3. Grindey GB, et al.
    Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024–4031.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Iwasaki H,
    2. Huang P,
    3. Keating MJ, et al.
    Differential incorporation of ara-C, gemcitabine and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90: 270–278.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Gandhi V,
    2. Legha J,
    3. Chen F, et al.
    Excision of 2′, 2′-difluorodeoxy cytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 1996; 56: 4453–4459.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Patel SR,
    2. Gandhi V,
    3. Jenkins J,
    4. Papadopolous N, et al.
    Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19: 3483–3489.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Look KY,
    2. Sandler A,
    3. Blessing JA, et al.
    Phase II trial of gemcitabine as second-line chemotherapy for uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004; 92: 644–647.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. van Hoesel QG,
    2. Verweij J,
    3. Catimel G, et al.
    Phase II study with docetaxel in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Am Oncol 1994; 5: 539–542.
    OpenUrl
  12. ↵
    1. Hensley ML,
    2. Maki R,
    3. Venkatraman E, et al.
    Gemcitabine and docetaxel in patients with unresectable liomyosarcoma: results of phase II trial. J Clin Oncol 2002; 20: 2824–2831.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Hensley ML,
    2. Anderson S,
    3. Soslow R, et al.
    Activity of gemcitabine plus docetaxel in leiomyosarcoma and other histologies: report of expanded phase II trial (ASCO 04). J Clin Oncol 2004; 22: 820 (abstract).
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. World Health Organization
    . WHO handbook for reporting results of cancer treatment: WHO offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979.
  15. ↵
    1. Trotti A,
    2. Colevas AD,
    3. Setser A, et al.
    CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–81.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Demetri GD,
    2. Elias AD.
    Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995; 9: 765–785.
    OpenUrlPubMedWeb of Science
    1. Gottlieb JA,
    2. Benjamin RS,
    3. Baker LH, et al.
    Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60: 199–203.
    OpenUrlPubMed
    1. Quirt I,
    2. Eisenhauer E,
    3. Bramwell V, et al.
    Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas. Cancer Treat Rep 1987; 71: 1109–1110.
    OpenUrlPubMed
    1. Goldstein D,
    2. Cheuvart B,
    3. Trump DL,
    4. Shiraki M, et al.
    Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 1990; 13: 420–423.
    OpenUrlPubMed
  20. ↵
    1. Palumbo R,
    2. Palmeri S,
    3. Antimi M, et al.
    Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997; 8: 1159–1162.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Leu KM,
    2. Ostruszka LJ,
    3. Shewach D, et al.
    Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22: 1706–1712.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Bay JO,
    2. Ray-Coquard I,
    3. Fayette J, et al.
    Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcoma: a retrospective analysis. Int J Cancer 2006; 119: 706–711.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Maki RG,
    2. Wathen JK,
    3. Patel SR, et al.
    Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25: 2755–2763.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords